Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by MasterAlgaeon Aug 28, 2020 10:17am

325 Views

Post# 31469197

A bit of FYI re: Stern IR

Stern IR was aquired by by Precision Medicine Group in 2018. Precision Medicine Group describes itself as "a global research, development, and commercialization partner, we leverage the discipline of precision medicine as our foundation and have invested accordingly, arming our experts with data and technology that enable us to solve challenges, produce actionable insights, and transform the process of bringing targeted new drugs to market."

Bullboard Posts

Anaergia expands relationship with PepsiCo